AMERICAN WELL CORP-CLASS A (AMWL) Fundamental Analysis & Valuation

NYSE:AMWL • US03044L2043

5.49 USD
-0.28 (-4.85%)
Last: Mar 12, 2026, 08:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AMWL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall AMWL gets a fundamental rating of 3 out of 10. We evaluated AMWL against 35 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for AMWL as it has an excellent financial health rating, but there are worries on the profitability. AMWL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. AMWL Profitability Analysis

1.1 Basic Checks

  • AMWL had negative earnings in the past year.
  • AMWL had a negative operating cash flow in the past year.
  • In the past 5 years AMWL always reported negative net income.
  • AMWL had a negative operating cash flow in each of the past 5 years.
AMWL Yearly Net Income VS EBIT VS OCF VS FCFAMWL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • AMWL has a Return On Assets (-29.56%) which is comparable to the rest of the industry.
  • AMWL has a Return On Equity (-40.62%) which is in line with its industry peers.
Industry RankSector Rank
ROA -29.56%
ROE -40.62%
ROIC N/A
ROA(3y)-63.93%
ROA(5y)-45.24%
ROE(3y)-84.79%
ROE(5y)-58.8%
ROIC(3y)N/A
ROIC(5y)N/A
AMWL Yearly ROA, ROE, ROICAMWL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • The Gross Margin of AMWL (53.79%) is worse than 62.86% of its industry peers.
  • AMWL's Gross Margin has improved in the last couple of years.
  • AMWL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y6.88%
AMWL Yearly Profit, Operating, Gross MarginsAMWL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AMWL Health Analysis

2.1 Basic Checks

  • AMWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AMWL has been increased compared to 1 year ago.
  • The number of shares outstanding for AMWL has been reduced compared to 5 years ago.
  • There is no outstanding debt for AMWL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMWL Yearly Shares OutstandingAMWL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
AMWL Yearly Total Debt VS Total AssetsAMWL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • Based on the Altman-Z score of -7.81, we must say that AMWL is in the distress zone and has some risk of bankruptcy.
  • AMWL's Altman-Z score of -7.81 is on the low side compared to the rest of the industry. AMWL is outperformed by 85.71% of its industry peers.
  • There is no outstanding debt for AMWL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.81
ROIC/WACCN/A
WACC9.44%
AMWL Yearly LT Debt VS Equity VS FCFAMWL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • AMWL has a Current Ratio of 3.37. This indicates that AMWL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.37, AMWL is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
  • AMWL has a Quick Ratio of 3.35. This indicates that AMWL is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AMWL (3.35) is better than 77.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 3.35
AMWL Yearly Current Assets VS Current LiabilitesAMWL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. AMWL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.57% over the past year.
  • AMWL shows a decrease in Revenue. In the last year, the revenue decreased by -1.98%.
  • Measured over the past years, AMWL shows a small growth in Revenue. The Revenue has been growing by 0.33% on average per year.
EPS 1Y (TTM)52.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.13%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.47%
Revenue growth 5Y0.33%
Sales Q2Q%-22.11%

3.2 Future

  • AMWL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
  • The Revenue is expected to decrease by -1.60% on average over the next years.
EPS Next Y34.92%
EPS Next 2Y23.79%
EPS Next 3Y18.72%
EPS Next 5Y11.1%
Revenue Next Year-19.18%
Revenue Next 2Y-8.22%
Revenue Next 3Y-4.1%
Revenue Next 5Y-1.6%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMWL Yearly Revenue VS EstimatesAMWL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M 250M
AMWL Yearly EPS VS EstimatesAMWL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. AMWL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AMWL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMWL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMWL Price Earnings VS Forward Price EarningsAMWL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMWL Per share dataAMWL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • AMWL's earnings are expected to grow with 18.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.79%
EPS Next 3Y18.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMWL Dividend Analysis

5.1 Amount

  • AMWL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMWL Fundamentals: All Metrics, Ratios and Statistics

AMERICAN WELL CORP-CLASS A

NYSE:AMWL (3/12/2026, 8:23:07 PM)

5.49

-0.28 (-4.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners38.93%
Inst Owner Change0%
Ins Owners3.54%
Ins Owner Change1.41%
Market Cap90.86M
Revenue(TTM)249.32M
Net Income(TTM)-95.70M
Analysts70.67
Price Target6.63 (20.77%)
Short Float %2.58%
Short Ratio3.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.58%
Min EPS beat(2)-9.03%
Max EPS beat(2)16.19%
EPS beat(4)3
Avg EPS beat(4)17.14%
Min EPS beat(4)-9.03%
Max EPS beat(4)31.2%
EPS beat(8)6
Avg EPS beat(8)10.13%
EPS beat(12)7
Avg EPS beat(12)-7.06%
EPS beat(16)10
Avg EPS beat(16)-4.37%
Revenue beat(2)2
Avg Revenue beat(2)2.02%
Min Revenue beat(2)1.14%
Max Revenue beat(2)2.89%
Revenue beat(4)4
Avg Revenue beat(4)5.4%
Min Revenue beat(4)1.14%
Max Revenue beat(4)8.93%
Revenue beat(8)5
Avg Revenue beat(8)2.14%
Revenue beat(12)5
Avg Revenue beat(12)0.15%
Revenue beat(16)5
Avg Revenue beat(16)-0.22%
PT rev (1m)-20.41%
PT rev (3m)-27.1%
EPS NQ rev (1m)12.58%
EPS NQ rev (3m)11.58%
EPS NY rev (1m)8.93%
EPS NY rev (3m)7.93%
Revenue NQ rev (1m)-10.95%
Revenue NQ rev (3m)-10.95%
Revenue NY rev (1m)-17.07%
Revenue NY rev (3m)-17.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-6.64
EYN/A
EPS(NY)-4.32
Fwd EYN/A
FCF(TTM)-3.99
FCFYN/A
OCF(TTM)-3.99
OCFYN/A
SpS15.06
BVpS14.23
TBVpS10.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.56%
ROE -40.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.79%
FCFM N/A
ROA(3y)-63.93%
ROA(5y)-45.24%
ROE(3y)-84.79%
ROE(5y)-58.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y6.88%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.06%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.37
Quick Ratio 3.35
Altman-Z -7.81
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)31.54%
Cap/Depr(5y)27.61%
Cap/Sales(3y)3.96%
Cap/Sales(5y)3.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.13%
EPS Next Y34.92%
EPS Next 2Y23.79%
EPS Next 3Y18.72%
EPS Next 5Y11.1%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.47%
Revenue growth 5Y0.33%
Sales Q2Q%-22.11%
Revenue Next Year-19.18%
Revenue Next 2Y-8.22%
Revenue Next 3Y-4.1%
Revenue Next 5Y-1.6%
EBIT growth 1Y55.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.27%
EBIT Next 3Y24.78%
EBIT Next 5Y16.34%
FCF growth 1Y53.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.21%
OCF growth 3YN/A
OCF growth 5YN/A

AMERICAN WELL CORP-CLASS A / AMWL FAQ

Can you provide the ChartMill fundamental rating for AMERICAN WELL CORP-CLASS A?

ChartMill assigns a fundamental rating of 3 / 10 to AMWL.


Can you provide the valuation status for AMERICAN WELL CORP-CLASS A?

ChartMill assigns a valuation rating of 0 / 10 to AMERICAN WELL CORP-CLASS A (AMWL). This can be considered as Overvalued.


Can you provide the profitability details for AMERICAN WELL CORP-CLASS A?

AMERICAN WELL CORP-CLASS A (AMWL) has a profitability rating of 1 / 10.